212 related articles for article (PubMed ID: 33778733)
21. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
22. CT texture analysis in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: A potential imaging biomarker for treatment response and prognosis.
Chee CG; Kim YH; Lee KH; Lee YJ; Park JH; Lee HS; Ahn S; Kim B
PLoS One; 2017; 12(8):e0182883. PubMed ID: 28797063
[TBL] [Abstract][Full Text] [Related]
23. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
24. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
[TBL] [Abstract][Full Text] [Related]
25. Prediction of Inflammatory Breast Cancer Survival Outcomes Using Computed Tomography-Based Texture Analysis.
Song SE; Seo BK; Cho KR; Woo OH; Ganeshan B; Kim ES; Cha J
Front Bioeng Biotechnol; 2021; 9():695305. PubMed ID: 34354986
[No Abstract] [Full Text] [Related]
26. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
[TBL] [Abstract][Full Text] [Related]
27. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy.
Yip C; Landau D; Kozarski R; Ganeshan B; Thomas R; Michaelidou A; Goh V
Radiology; 2014 Jan; 270(1):141-8. PubMed ID: 23985274
[TBL] [Abstract][Full Text] [Related]
28. CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes.
Lubner MG; Stabo N; Abel EJ; Del Rio AM; Pickhardt PJ
AJR Am J Roentgenol; 2016 Jul; 207(1):96-105. PubMed ID: 27145377
[TBL] [Abstract][Full Text] [Related]
29. Preoperative Prediction of BRAF Mutation Status in Colorectal Cancer Using a Clinical-radiomics Model.
Xue T; Peng H; Chen Q; Li M; Duan S; Feng F
Acad Radiol; 2022 Sep; 29(9):1298-1307. PubMed ID: 35033450
[TBL] [Abstract][Full Text] [Related]
30. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
Chaddad A; Sabri S; Niazi T; Abdulkarim B
Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
[TBL] [Abstract][Full Text] [Related]
31. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
[TBL] [Abstract][Full Text] [Related]
32. CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma.
Bonnin A; Durot C; Barat M; Djelouah M; Grange F; Mulé S; Soyer P; Hoeffel C
Diagn Interv Imaging; 2022 Feb; 103(2):97-102. PubMed ID: 34666945
[TBL] [Abstract][Full Text] [Related]
33. Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach.
Guerrisi A; Russillo M; Loi E; Ganeshan B; Ungania S; Desiderio F; Bruzzaniti V; Falcone I; Renna D; Ferraresi V; Caterino M; Solivetti FM; Cognetti F; Morrone A
Front Oncol; 2021; 11():704607. PubMed ID: 34692481
[TBL] [Abstract][Full Text] [Related]
34. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
[TBL] [Abstract][Full Text] [Related]
35. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
36. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
[TBL] [Abstract][Full Text] [Related]
37. Virtual monoenergetic imaging in rapid kVp-switching dual-energy CT (DECT) of the abdomen: impact on CT texture analysis.
Baliyan V; Kordbacheh H; Parameswaran B; Ganeshan B; Sahani D; Kambadakone A
Abdom Radiol (NY); 2018 Oct; 43(10):2693-2701. PubMed ID: 29541830
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
[TBL] [Abstract][Full Text] [Related]
39. Class 1, 2, and 3
Schirripa M; Biason P; Lonardi S; Pella N; Pino MS; Urbano F; Antoniotti C; Cremolini C; Corallo S; Pietrantonio F; Gelsomino F; Cascinu S; Orlandi A; Munari G; Malapelle U; Saggio S; Fontanini G; Rugge M; Mescoli C; Lazzi S; Reggiani Bonetti L; Lanza G; Dei Tos AP; De Maglio G; Martini M; Bergamo F; Zagonel V; Loupakis F; Fassan M
Clin Cancer Res; 2019 Jul; 25(13):3954-3961. PubMed ID: 30967421
[TBL] [Abstract][Full Text] [Related]
40. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.
Tie J; Gibbs P; Lipton L; Christie M; Jorissen RN; Burgess AW; Croxford M; Jones I; Langland R; Kosmider S; McKay D; Bollag G; Nolop K; Sieber OM; Desai J
Int J Cancer; 2011 May; 128(9):2075-84. PubMed ID: 20635392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
